港股異動 | 現代牙科(3600.HK)股價腰斬 種植牙今年將成為集採重點關注對象
格隆匯1月28日丨現代牙科(3600.HK)跌4.49%,報4.89港元,自去年8月見11港元的歷史最高價以來,股價已經腰斬,最新總市值47億港元。1月10日,國務院常務會議召開,決定常態化制度化開展藥品和高值醫用耗材集中帶量採購,進一步降低患者醫藥負擔。明確指出對羣眾關注的骨科耗材、藥物球囊、種植牙等分別在國家和省級層面開展集採。這是國家層面首次提出對種植牙開展集採,將種植牙納入到了國家和省級層面的醫保集採當中。近年來,國家組織藥品集中帶量採購,所採藥品平均降價了54%。有專家預測這回種植牙可能降低60%-90%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.